ClinicalTrials.gg
CompletedNCT03375957Updated May 7, 2018

Sensitization Study of ATx201 in Healthy Volunteers

A Phase 1 interventional study of ATx201 and ATx201 Placebo Gel in Sensitivity, Contact, sponsored by UNION therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-07.

Sponsored by UNION therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 8 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase I, single-site study to evaluate the sensitization potential of topically applied ATx201 GEL, 2% and 4%, along with a placebo control, in healthy human subjects.

02

Conditions studied

  • Sensitivity, Contact

Browse trials for

03

In context

Dermatitis, Contact

61 studies on the registry are indexed under Dermatitis, Contact; 8 are open to participants now.

This study's enrollment of 240 is above the median of 47 across 49 interventional studies indexed under Dermatitis, Contact.

Browse Dermatitis, Contact studies →

Lead sponsor

UNION therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good general health
  • no less than 19.0 and no greater than 36.0 kg/m² (inclusive).
  • Demonstrates a Fitzpatrick skin score of I - IV
  • Female subjects must agree to use acceptable methods from the Screening Visit through 90 days after the End of Study (EOS) Visit; or status with no menses for at least 1 year prior to the Screening Visit.
  • Willing to refrain from excessive consumption of sodium in food or beverage 48 hours prior to Day 1 through EOS Visit.
  • Willing to shower using the same non-medicated soap/cleansers, and abstain from excessive sun exposure (including tanning salons) from the Screening Visit through EOS Visit.

Exclusion criteria

Exclusion Criteria:

  • Reports a history of diabetes mellitus, asthma (acceptable if no episode within 5 years prior to Day 1), or currently diagnosed with hypertension or circulatory disease.
  • Reports use of any oral, nasal or topical , or oral or topical retinoids (other than Vitamin A at normal dietary amounts)
  • Reports a significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
  • Reports a history of significant skin conditions or disorders such as psoriasis, atopic dermatitis, etc.
  • Reports a history of significant dermatologic cancers.
  • Displays an obvious difference in skin color between upper arms or upper back or the presence of a skin anomaly
  • Reports smoking or use of tobacco or nicotine delivery products within 14 days prior to Day 1 through EOS Visit.
  • Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator.
  • A female who is pregnant, lactating, breastfeeding, or intends to become pregnant over the course of the study.
  • Reports a history of drug or alcohol addiction or abuse within the past year.
  • Reports having donated blood or plasma within 48 hours prior to Day 1 through EOS Visit.
  • Subject exhibits excessive hair density on the upper arms or back such that patch adhesion could be compromised.
  • Subject reports undergoing hair depilation (e.g. chemical, laser, physical) within 30 days prior to Day 1 through EOS Visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    ATx201 2% Gel

    Drug: ATx201

  • Experimental
    ATx201 4% Gel

    Drug: ATx201

  • Placebo comparator
    ATx201 Gel Placebo

    Drug: ATx201 Placebo Gel

Interventions

  • DrugATx201

    two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms

  • DrugATx201 Placebo Gel

    two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms

06

What researchers measure

Primary outcomes

  1. Dermal Response Score

    number of patients with a dermal response score of at least 2

    Time frame: 21 days

Secondary outcomes

  1. Dermal Response and Effects Score

    number of patients with a dermal response and effects score of at least 3

    Time frame: 21 days

07

Study locations

1 site
  • Bio-Kinetic Clinical Applications, LLC
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03375957
Lead sponsor
UNION therapeutics
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Jan 8, 2018
Primary completion
Feb 17, 2018
Completion
Mar 15, 2018
Last update
May 7, 2018

Study contacts

Philippe Prokocimer, MD
study director · CMO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ATX201

Start the discussion